The article provides an overview of the approach to be applied when calculating regulatory fees associated with registration and authorization for medicines intended to be marketed and used in Ireland.
The article describes in detail the approach to be applied with respect to clinical performance testing considerations including, inter alia, the ones associated with treatment parameters and protocols, safety and effectiveness endpoints and data, as well as adverse events